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ABSTRACT 
Objective: Famotidine an H2 receptor antagonist is the drug of choice to treat ulcers in stomach (gastric and duodenal), erosive esophagitis 
(heartburn or acid indigestion) and gastroesophageal reflux disease (GERD). Drug molecules with limited aqueous solubility are becoming very 
common in the research and development portfolios of discovery focused pharmaceutical companies. Prodrugs are an established concept to 
overcome barriers like poor solubility to drug’s usefulness. Polar Amino acids which are biocompatible and easily ionisable were chosen as 
promoiety for the formation of prodrugs. Aqueous solubility is an important parameter to enhance the bioavailability of the drug. Hence the present 
study aims to enhance aqueous solubility and in turn bioavailability by prodrug approaches. 
Methods: Synthesis of novel amino acid prodrug of famotidine was done by microwave irradiation technique. The synthesized amino acid prodrug 
was characterized by IR, NMR, Mass and DSC. 
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Results: In vitro chemical hydrolysis profiles revealed that the synthesized amino acid derivative of famotidine was chemically stable in Simulated 
Gastric fluid pH 1.2 and Simulated Intestinal Fluid pH 7.4. Decrease in Log P value,-0.39 of amino acid prodrug compared to-0.60 of famotidine was 
observed. 
Conclusion: Hence a novel amino acid prodrug of famotidine with better solubility and bioavailability was synthesized and characterized. 
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INTRODUCTION 
Famotidine (FM) chemically 3-([2-(diaminomethylene amino) 
thiazol-4-yl] methyl-thio)-N' sulfamoyl propimidamide is a 
histamine H2 receptor blocker (fig. 1).  
 
 
Fig. 1: Chemical structure of famotidine 
 
FM is used to treat and prevent ulcers in the stomach and intestine 
[1]. FM is a poorly water soluble drug and is poorly absorbed from 
the lower gastrointestinal tract. Dissolution is the rate limiting step 
in the process of drug absorption [2]. There are many stated 
techniques for solubility enhancement of FM like complexation, solid 
dispersion, micronization [3-5]. Prodrug is an efficient technique to 
enhance solubility of drugs. Prodrugs are defined as a biologically 
inactive derivative of a parent drug molecule that usually requires a 
chemical or enzymatic transformation within the body to release the 
active drug, and possess improved delivery properties over the 
parent molecule [6]. There are no reported methods for preparation 
of amino acid prodrug in solubility enhancement of FM. The main 
purpose of the present study is to increase aqueous solubility of 
famotidine by prodrug approach. Amino acids do have proven 
record of being successfully used as promoieties in synthesis of 
prodrugs. As amino acids are biocompatible and easily ionisable, 
synthesis of amino acid prodrug can be used for enhancing the 
solubility. New drug research consumes a lot of money and time, 
whereas prodrug strategy enhances the effectiveness of existing 
drug by overcoming its drawbacks. Therapy enhancement via 
successful delivery of a therapeutic agent is the principal goal of 
drug delivery research. Achieving therapeutic efficacy of any 
pharmaceutical dosage form mainly depends upon the availability of 
drug with the desired concentration to the target site [7]. The 
bioavailability of poorly water-soluble drug like FM is a well known 
difficulty to be coped with during drug delivery. The current 
research aims to resolve the aforementioned issue by prodrug 
approach. Amino acid prodrug of FM was synthesized and the 
synthesized prodrug was investigated by FT-IR, 1H1 NMR, mass and 
DSC studies. Aqueous solubility studies of prodrug were performed 
to ensure solubility enhancement. 
MATERIALS AND METHODS  
Instruments and chemicals 
Melting points were determined on a Differential Scanning 
Calorimeter (DSC) apparatus. Aluminum sheets were coated with 
silica gel 60 F254 of Merck were used for TLC. Photo microscopic 
images were taken using an Olympus research microscope. 
Elemental analysis was performed using Carlo-Erba model 1108. 
The IR spectra were recorded in Agilent cary 630 FT-IR 
spectrophotometer and wave numbers are reported in cm-1. The 
1H1NMR spectra were obtained on a Bruker Avance-300 
spectrometer (300 MHz) in deutrated methanol. Chemical shifts 
were recorded in ppm (d) relative to TMS as an internal standard. 
High resolution mass spectra were recorded on an Agilent 5975 
MSD series Direct Inlet Probe system using electro spray ionization 
technique. All chemicals used were of analytical grade procured 
from SD fine, Himedia, and E. Merck while standard drug of 
Famotidine was purchased from Yarrow Chem Products, Mumbai.  
Synthesis of amino acid prodrug 
Water soluble amino acid prodrug of Famotidine (FM1) was 
synthesized by using polar amino acid Glycine as promoeity. 
Microwave irradiation technique was chosen, as the reaction time is 
short, less laborious, more yield and also it suits green chemistry. 
Imidazole was selected as the base due to its promotion ability, 
efficient microwave absorption and also it homogenizes the reaction 
mixture in dry medium [8].  
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Famotidine comprises of four reactive amine groups which may 
interfere in the prodrug synthesis. Hence except the intended amine 
group remaining amines will be protected for efficient synthesis of 
prodrugs. The tert-Butyloxycarbonyl (Boc) group is a commonly 
used protecting group for amines particularly in peptide synthesis. 
Formation of Boc amines (Boc protected amine groups) occurs in 
aqueous or anhydrous conditions on reaction of base and anhydride 
After the reaction between Boc protected Famotidine and Glycine, 
the amino acid derivatives of Famotidine with Boc protection was 
deprotected completely within ten minutes using mineral acids like 
Hydrochloric acid and dioxane as solvent.  
Boc protection of reactive amine groups in famotidine  
Accurately weighed amount of 2 mM of Famotidine was treated with 
3.6 equivalents of di tertiary butyl di carbonate (Boc) group. The 
reaction mixture was dissolved in 100 ml of water and saturated 
solution of sodium bicarbonate was added. To the above solution 15 
ml of tetrahydrofuran (THF) was added. The mixture was heated at 
33◦C for 45 min (fig. 2) and Boc protected compound was obtained [9].  
 
 
Fig. 2: t-boc protection of amine groups in famotidine 
 
Reaction of amino acid with boc protected famotidine  
Accurately weighed quantity of 1 mM of Glycine amino acid, 2 mM of 
Boc protected Famotidine drug and 1 mM of imidazole was taken and 
physically ground by using mortar and pestle. Then the mixture was 
homogenized with ultra-homogenizer for 3 min and then the reaction 
mixture was exposed to microwave irradiation in a domestic 
microwave oven for 160 sec. Crude product was obtained [10] (fig. 3). 
 
 
Fig. 3: Synthesis of amino acid prodrug of famotidine 
Boc-deprotection  
The resultant Boc protected amino acid derivative of Famotidine 
was treated with 9 equivalents of 1M Hcl and 5 ml of dioxane. The 
mixture was refluxed for 1 hr. The resulting product was filtered and 
the filtrate was washed several times with dioxane [11-13]. TLC 
analysis was performed to ensure the removal of Boc groups. The 
residue was dried weighed and the yield was calculated (fig. 4). 
 
 
Fig. 4: t-boc deprotection 
 
Purification 
Synthesised product was purified by using column chromatography 
using silica gel as adsorbent and ethyl acetate/methanol/water 
(8:1.5:0.3 v/v/v) as mobile phase. The purified product was 
recrystallised by using methanol. 
Further qualitative analysis of compound was performed by HPLC 
analysis using Acetonitrile: Water: Triethyl amine: Orthophosporic acid 
(49.9: 49.9:0.1: 0.1%v/v/v/v) at a detection wavelength of 280 nm. TLC 
analysis was performed to ensure purity of the compound (fig. 5). 
 
 
Fig. 5: HPLC spectrum of aminoacid prodrug FM1 
 
Spectral and thermal characterization 
Pressed pellet technique was adapted for FT-IR analysis. Drug 
admixed with KBr were made in to the disc and was analysed in the 
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spectral range of 4000 to 400 cm-1and IR spectrum was recorded. 
1H1, C[13] NMR, Mass and DSC studies were carried out for the 
synthesized prodrug. 
Partition coefficient 
The partition coefficient of the product was determined in n-
octanol/water system (10:10) by standard technique. Product (drug 
or prodrug) was accurately weighed (10 mg) and added to 10 ml of 
each n-octanol and aqueous phase. The mixture was shaken using a 
mechanical shaker for 24 h until equilibrium was reached. Phases 
were separated by separating funnel and aqueous phase was 
analyzed for the amount of product after appropriate dilution. 








Where Kd is partition coefficient 
Co = Concentration of solute distributed organic phase  
Caq = Concentration of solute distributed in aqueous phase 
Aqueous solubility 
Equilibrium solubility was determined by a “shake-flask” method 
[15]. The aqueous solubility of the compound was determined by 
adding an excess amount of a drug beyond its saturation limit in 
sealed conical flask containing 10 ml of water. This conical flask is 
placed in a mechanical shaker for 48 h (this duration was previously 
tested to be sufficient to reach equilibrium). The solvent was filtered 
through Whatmann filter paper No.42 and the portion of the filtrate 
was suitably diluted with water. Solutions were analyzed by using 
UV spectrophotometer at 281 nm, which was the absorption maxima 
and drug concentrations were calculated [16]. 
Chemical hydrolysis study 
The rate of chemical hydrolysis of the prodrug was determined in 
Simulated Gastric Fluid (SGF, pH 1.2) and Simulated Intestinal Fluid 
(SIF, pH 7.4) at 37 °C. Solution of 10 mg of the synthesized prodrug 
was placed in dissolution basket containing 90 ml of SGF/SIF 
individually. An aliquot of 15 ml of this solution was withdrawn 
repeatedly and kept in test tubes maintained at 37±0.5 °C. At a definite 
interval of time (0.5, 1, 2 up to 8h), an aliquot was withdrawn to 
different test tubes and was transferred to micro centrifuge tubes 
followed by addition of methanol to make up the volume. The tubes 
were placed in a freezing mixture in order to arrest further hydrolysis, 
followed by vortexing at high speed for 5 min. After vortexing, the 
tubes were centrifuged at high speed 3000rpm for 5 min. A 5 ml of 
clear supernatant obtained from each tube was measured on UV 
spectrophotometer for the amount of free drug released after the 
hydrolysis of prodrug in SGF and SIF at 281 nm [17]. 
RESULTS AND DISCUSSION 
Amino acid prodrug of FM was synthesized by using microwave 
irradiation and its percentage yield was found to be 93.68%. TLC 
studies have shown the Rf values of FM and its amino acid prodrug 
to be 0.67 cm and 0.56 cm respectively, which ensures the formation 
of prodrug.  
A photo microscopic image of FM and its amino acid prodrug was 
observed at 45X (fig. 6). Morphology of the synthesized amino acid 
prodrug was different from that of FM. Elemental analysis of synthesized 




Fig. 6: Microscopical characterization of compounds (a) FAM (b) FM1 amino acid prodrug of famotidine 
 
The characteristic N-H stretch of amine in famotidine shifted in amino 
acid prodrug spectrum from 3401.8 cm-1 to 3200.1 cm-1. The carbonyl 
group formed in aminoacid prodrug and shown C=O stretch at 1581.9 
cm-1. Hence there is an interaction of N-H group of drug with C=O 
group of glycine resulting in formation of amide bond (-CONH) 
confirming the amino acid prodrug formation (fig.7 and fig. 8). 
 
 
Fig. 7: FT-IR spectra of famotidine 
 
Fig. 8: FT-IR spectra of amino acid prodrug of famotidine 
 
1H1NMR of amino acid prodrug of FM (CD3OD) δ in ppm: 8.56 (s, 2H, 
NH2 protons of sulfonamide), 7.34 (d, 1H, Heterocyclic protons), 
4.45 (s, 2H, CH2 protons), 3.92 (s, 2H, CH2 protons), 3.62 (s, 2H, 
CH2methylene), 2.61 (t, 2H,-CH2 protons), 1.89 (t, 2H,-CH2protons), 
1.53 (s, 2H, NH2 protons). There is an increase in the number of 
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protons and signal for characteristic NH2 group in FM1compared to 
famotidine (fig. 9 and fig. 10). C[13]NMR of aminoacid prodrug of FM 
(CD3OD) δ in ppm: 28.42, 31.93, 39.24, 50.11, 108.26, 139.14, 
148.12, 152.44, 164.56, 170.11 (fig. 11). 
 
 
Fig. 9: NMR spectra of famotidine 
 
 




Fig. 11: 13C NMR of synthesized amino acid prodrug of 
famotidine (FM 2) 
 
Mass spectrum of FM represents characteristic parent ion peak at 
m/z = 336 (M-1 peak, C8H15N7O2S3) and a base peak at m/z value = 
80 (fig. 12). The mass spectrum of synthesized amino acid prodrug 
of FM exhibits parent ion peak at m/z = 410 (M+peak, C10H18N8O4S3), 
from parent peak, guanidine has been cleaved leaving N'-(N-(2-
aminoacetoxy)sulfamoyl)-3-((2,3-dihydrothiazol-4-yl) methylthio) 
propanimidamide of m/z = 354, C9H15N5O4S3. Further fragments like 
N-(2-aminoacetoxy) sulfonic amide (m/z = 155, C2H6N2O4S), (2,3-
dihydrothiazol-4-yl) methanethiol (m/z = 131, C4H7NS2), 2,3-
dihydrothiazole (m/z = 87, C3H3NS) and guanidine (m/z = 60, CH5N3, 
base peak) were formed (fig. 13). 
 
Fig. 12: Mass spectra of famotidine 
 
 
Fig. 13: Mass spectra of synthesized amino acid prodrug of 
famotidine (FM1) 
 
From the IR, NMR & Mass studies, the molecular structure for 
synthesized amino acid prodrug was predicted and the proposed 
structure was confirmed to be an amino acid derivative of 
famotidine and the molecular formula was found to be C10H18N8O4S3. 
DSC experiments were carried out to study the thermal behavior of 
the synthesized prodrug in relation to the individual drug. DSC study 
of FM shows an endothermic peak at 166.4 °C, while DSC study of 
amino acid prodrug shows sharp endothermic peaks at 148.47 °C 
respectively. Sharp endothermic values of synthesized prodrug and 
the individual drug agreed with the measured melting range in the 
melting point determination. The thermal profile of the synthesized 
prodrug was distinct, with a different melting transition from that of 
the individual drug. This indicates the formation of novel prodrug 
(fig. 14 and fig. 15). 
 
 
Fig. 14: DSC thermogram of famotidine 
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Fig. 15: DSC thermogram of amino acid prodrug of famotidine 
 
Log P value was calculated from partition coefficient studies and was 
found to be-0.60 and-0.39 for drug and prodrug respectively. 
Decrease in log P values ensures increase in hydrophilic character of 
the synthesized prodrug. 
Aqueous solubility of FM and amino acid prodrug was calculated in 
mg/ml and was found to be 2.386 and 18.565 for FM and prodrug of 
FM respectively. The solubility of prodrug FM1 enhanced by 7.8 
folds when compared to pure drug (fig. 16) 
 
Fig. 16: Comparative aqueous solubility studies of drug and 
prodrug 
 
* Error bars represent standard deviation of the mean (n=3) 
Chemical hydrolysis study of amino acid prodrug in buffer solutions 
(Simulated Gastric Fluid, pH 1.2 and Simulated Intestinal Fluid, pH 
7.4) at 37 °C was performed. The Rate of hydrolysis, Hydrolysis 
constant and t½ of synthesized amino acid prodrug was found to be 
92.45% and 98.52% at 300 min and 7hr, 6.81 × 10-3and 3.28 × 10-3, 
102 and 204 min in SGF and SIF respectively (table 1 and table 2).
 
Table 1: Kinetic data for the chemical hydrolysis of FM1 in SGF 
Amino acid Prodrug (FM1) pH Percent of Chemical hydrolysis Kobs 
(min-1) 
t1/2 (min) 
30 min 60 min 90 min 120 min 150 min 210 min 300 min 
SGF 1.2 37.01 41.12 45.64 54.15 60.93 70.48 92.45 6.81*10-3 102 
 
Table 2: Kinetic data for the chemical hydrolysis of FM1 in SIF 
Amino acid Prodrug (FM1) pH Percent of Chemical hydrolysis Kobs 
(min-1) 
t1/2 (min) 
1hr  2hr 3hr 4hr 5hr 6hr 7hr 
SIF 7.4 6.11 28.45 32.33 49.15 60.23 91.41 98.52 3.28*10-3 204 
 
Amino acid prodrug improves drugability of complex molecules 
[18]. Though earlier we reported synthesis of sulphoxide prodrug of 
famotidine [14], amino acid prodrug of famotidine was found to be 
better in terms of solubility enhancement as we observed 7.8 fold 
increment in solubility of famotidine whereas in sulphoxide prodrug 
it was found to be 6.7 folds. Moreover amino acids are 
biocompatible, easy to be metabolized in vivo compared to other 
organic groups used as promoeities. Microwave assisted synthesis is 
a vital technique in green chemistry. Green chemistry aims to 
remove hazards at the design stage. The practice of eliminating 
hazards from the beginning of the chemical design process has 
benefits for our health and the environment [19]. The synthesis 
adopted in the present study was microwave assisted irradiation 
technique which is an eco friendly method.  
CONCLUSION 
Novel amino acid prodrug of famotidine was successfully synthesized 
by using microwave irradiation technique with imidazole as base 
which suits green chemistry. Prepared prodrug exhibits good 
solubility, reasonable in vitro chemical stability in acidic and alkaline 
medium. Partition coefficient study ensures the increase in 
hydrophilicity of the synthesized prodrug. These properties make the 
novel amino acid prodrug of famotidine effective in treating gastro 
intestinal problems with enhanced bioavailability. 
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